A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer

By sjmartinez • March 25, 2024

Cristea MC, Stewart D, Synold T, Ruel N, Mortimer J, Wang E, Jung A, Wilczynski S, Konecny GE, Eng M, Kilpatrick L, Han E, Dellinger T, Hakim A, Lee S, Morgan RJ, Wakabayashi MT, Frankel PH. A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer. Gynecol Oncol. 2024 Mar;182:124-131. doi: 10.1016/j.ygyno.2023.12.017. Epub 2024 Jan 22. PMID: 38262235.

Tags: Endometrial cancer, Epithelial ovarian cancer, Folate receptor alpha, FRα, gemcitabine, Hematology/Oncology, MIRV, Mirvetuximab soravtansine, Platinum-resistance, Publications, Triple negative breast cancer

Interaction between APOE Ɛ4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study

Duivon M, Christy F, Thomas E, Lequesne J, Castel H, Gaudin C, Delmas D, Boyault S, Rigal O, Bousrih C, Lévy C, Lerebours F, Di[...]

Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer. Reply

Bardia A, Schwaederle M, Curigliano G. Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer. Reply. N Engl J Med. 2025 Feb 20;392(8):830-831. doi:[...]

Frailty: Can a Biological Aging Marker Enhance Precision Risk Assessment of Cancer Therapy Cardiotoxicity?

Sedrak MS, Asnani A. Frailty: Can a Biological Aging Marker Enhance Precision Risk Assessment of Cancer Therapy Cardiotoxicity? JACC CardioOncol. 2025 Feb;7(2):122-124. doi: 10.1016/j.jaccao.2025.01.004. PMID:[...]